Tirzepatide and Sleep Quality: Insights from the SURMOUNT-OSA Substudy Data

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated...

# Tirzepatide and Sleep Quality: Insights from the SURMOUNT-OSA Substudy Data

Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated remarkable efficacy in weight management and glycemic control. Beyond these primary indications, growing evidence, particularly from the SURMOUNT-OSA clinical trials, highlights its significant positive impact on sleep quality, especially in individuals with obstructive sleep apnea (OSA) and obesity.

The SURMOUNT-OSA Trials: A Deep Dive into Sleep Outcomes

The SURMOUNT-OSA program comprised two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials designed to evaluate the efficacy and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity [1, 2]. These trials provided crucial data on how tirzepatide influences various sleep-related parameters.

Key findings from the SURMOUNT-OSA trials include:

Reduction in Apnea-Hypopnea Index (AHI): Tirzepatide significantly reduced the AHI, a primary measure of OSA severity. Participants receiving tirzepatide experienced a substantial decrease in the number of apnea and hypopnea events per hour of sleep, with reductions of up to nearly two-thirds [3, 4]. This improvement was observed in patients both with and without continuous positive airway pressure (CPAP) therapy.

Improved Patient-Reported Outcomes: Beyond objective measures, tirzepatide treatment was associated with improved quality of sleep, sleep-related functioning, and health-related quality of life (HRQoL) among people with OSA and obesity [5]. Patient-reported outcomes, such as the Epworth Sleepiness Scale and the Functional Outcomes of Sleep Questionnaire, showed clinically meaningful improvements, indicating reduced daytime fatigue and better overall sleep satisfaction [6].

Reduction in Hypoxic Burden: The trials also demonstrated a reduction in hypoxic burden, meaning less time spent with low oxygen levels during sleep. This is a critical outcome, as chronic intermittent hypoxia is a major contributor to the cardiovascular and metabolic complications associated with OSA [1].

Impact on Body Weight: The improvements in OSA severity and sleep quality were strongly linked to tirzepatide-induced weight loss. Obesity is a primary risk factor for OSA, and the significant weight reduction achieved with tirzepatide (up to 20% of body weight) directly contributes to the amelioration of airway obstruction [1, 3].

Mechanisms Underlying Improved Sleep Quality

The beneficial effects of tirzepatide on sleep quality are primarily mediated through its profound impact on weight loss. The mechanisms include:

Reduced Adipose Tissue: Weight loss, particularly around the neck and pharyngeal area, reduces the external compression on the upper airway, thereby decreasing the likelihood of airway collapse during sleep. This directly addresses the anatomical obstruction characteristic of OSA.

Decreased Inflammation: Obesity is associated with chronic low-grade inflammation, which can contribute to OSA pathogenesis. Tirzepatide's anti-inflammatory effects, evidenced by reductions in markers like hsCRP, may further contribute to improved respiratory function during sleep [1, 7].

Metabolic Improvements: Better glycemic control and insulin sensitivity, also achieved with tirzepatide, can indirectly support overall physiological health, which is conducive to better sleep.

New Therapeutic Option for OSA: Tirzepatide offers a promising new therapeutic avenue for individuals with OSA and obesity, particularly those who may not tolerate or adhere to traditional CPAP therapy. It provides a pharmacological approach to address the underlying obesity contributing to OSA.

Holistic Patient Care: By addressing both obesity and OSA, tirzepatide can lead to a more holistic improvement in patient health, reducing cardiovascular risk factors and enhancing overall quality of life.

Consideration in Treatment Algorithms: Clinicians should consider tirzepatide as a viable treatment option for eligible patients, integrating it into comprehensive management plans for obesity-related OSA.

It is important to note that while tirzepatide significantly improves OSA, it does not increase energy or alertness, so users typically do not experience sleep disruptions associated with stimulant-based medications [9].

References

[1] Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity - https://www.nejm.org/doi/abs/10.1056/NEJMoa2404881

[2] Study Details | NCT05412004 | Obstructive Sleep Apnea ... - https://clinicaltrials.gov/study/NCT05412004

[3] Tirzepatide reduced sleep apnea severity by up to nearly two ... - https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-sleep-apnea-severity-nearly-two-thirds

[4] What clinicians should know about prescribing tirzepatide ... - https://aasm.org/what-clinicians-should-know-about-prescribing-tirzepatide-for-sleep-apnea/

[5] Effect of tirzepatide treatment on patient-reported outcomes ... - https://www.sciencedirect.com/science/article/pii/S1389945725003946

[6] Zepbound and Insomnia: Risk Factors and Prevention Tips - GoodRx - https://www.goodrx.com/well-being/sleep/zepbound-insomnia?srsltid=AfmBOoowLumxOQv2Lkk40_DUR5QwQwvmEeAH-uNYbdamLj2ZvkfFHyhCkU

[7] Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial - https://www.nature.com/articles/s41591-025-04071-1

[8] Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight - https://www.sciencedirect.com/science/article/pii/S1389945725005283

[9] Will Tirzepatide Keep Me Awake at Night or Disrupt My Sleep? - https://drfortino.net/blog/does-tirzepatide-affect-sleep-quality/